News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
13,553 Results
Type
Article (2512)
Company Profile (3)
Press Release (11038)
Section
Business (5135)
Career Advice (72)
Deals (865)
Drug Delivery (6)
Drug Development (2302)
Employer Resources (6)
FDA (402)
Job Trends (696)
News (8569)
Policy (972)
Tag
Academia (40)
Africa (55)
Allergies (2)
Alliances (1321)
ALS (5)
Alzheimer's disease (14)
Antibody-drug conjugate (ADC) (2)
Approvals (400)
Artificial intelligence (5)
Asia (751)
Australia (92)
Bankruptcy (6)
Best Places to Work (470)
C2C Services and Suppliers (234)
California (81)
Canada (11)
Cancer (16)
Career advice (53)
Cell therapy (3)
China (12)
Clinical research (1802)
Collaboration (4)
Complete response letters (3)
COVID-19 (199)
C-suite (2)
Cystic fibrosis (2)
Data (17)
Diabetes (10)
Diagnostics (53)
Drug pricing (6)
Earnings (1210)
Employer resources (5)
Europe (4125)
Events (977)
Executive appointments (9)
FDA (409)
Florida (3)
Funding (3)
Gene editing (2)
Gene therapy (2)
GLP-1 (70)
Government (215)
Healthcare (280)
Hotbed/Location (6297)
Immunology and inflammation (3)
Infectious disease (202)
Inflammatory bowel disease (5)
Interviews (12)
IPO (202)
Job creations (240)
Job search strategy (53)
Layoffs (37)
Legal (235)
Lung cancer (3)
Manufacturing (5)
Massachusetts (22)
Medical device (53)
Medtech (53)
Mergers & acquisitions (660)
Metabolic disorders (17)
Multiple sclerosis (9)
Neurodegenerative disease (3)
Neuroscience (30)
New Jersey (7)
New York (36)
NextGen Class of 2024 (154)
Non-profit (64)
North Carolina (3)
Northern California (65)
Obesity (6)
Opinion (24)
Pennsylvania (11)
People (2189)
Phase I (502)
Phase II (679)
Phase III (854)
Pipeline (4)
Podcasts (5)
Policy (2)
Postmarket research (161)
Preclinical (148)
Radiopharmaceuticals (5)
Rare diseases (9)
Real estate (160)
Recruiting (3)
Regulatory (599)
Research institute (43)
Resumes & cover letters (12)
RSV (3)
Series A (2)
South America (60)
Southern California (17)
Special edition (3)
Startups (134)
Supply chain (2)
The Weekly (4)
United States (164)
Utah (3)
Vaccines (43)
Weight loss (8)
Date
Today (7)
Last 7 days (16)
Last 30 days (74)
Last 365 days (807)
2024 (605)
2023 (759)
2022 (1570)
2021 (1380)
2020 (1158)
2019 (777)
2018 (636)
2017 (830)
2016 (748)
2015 (896)
2014 (564)
2013 (494)
2012 (502)
2011 (503)
2010 (466)
13,553 Results for "sanofi".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
FDA
Sanofi and Regeneron’s Dupixent Snags First Biologic Approval in COPD
Already approved in six indications, Sanofi and Regeneron can now add chronic obstructive pulmonary disease to the list for their blockbuster injection.
September 27, 2024
·
2 min read
·
Kate Goodwin
Approvals
Sanofi Secures First-Line Nod for Sarclisa in Multiple Myeloma, Tees Up Competition With J&J
With Friday’s approval, Sanofi’s anti-CD38 antibody Sarclisa will go head-to-head with the first such therapy for multiple myeloma, Johnson & Johnson’s Darzalex, which raked in nearly $10 billion last year.
September 23, 2024
·
2 min read
·
Tristan Manalac
Multiple sclerosis
Roche Touts Phase II MS Data on Heels of Sanofi’s Late-Stage Stumbles
Days after Sanofi reported back-to-back failures for its BTK inhibitor, Roche’s fenebrutinib on Wednesday scored a mid-stage win in relapsing multiple sclerosis, demonstrating near-total elimination of disease activity.
September 4, 2024
·
2 min read
·
Tristan Manalac
Editorial
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two late-stage relapsing MS studies.
September 6, 2024
·
3 min read
·
Greg Slabodkin
Deals
Sanofi Dips Into Red-Hot Radiopharma Space With $110M Licensing Deal
Sanofi will join Big Pharma peers Novartis, BMS and Eli Lilly in radioligands, striking a $110 million licensing deal with RadioMedix and Orano Med to develop AlphaMedix for neuroendocrine tumors.
September 12, 2024
·
1 min read
·
Annalee Armstrong
GLP-1
As Novo and Lilly Focus on a Few Big Markets, Sanofi Seeks Global Reach for Diabetes GLP-1 Drug
Experts say Novo Nordisk and Eli Lilly’s GLP-1 drugs are unlikely to reach more countries in the near term, but Sanofi’s diabetes treatment has gained ground globally.
August 21, 2024
·
5 min read
·
Patience Asanga
Earnings
Vir Lays Off 25% of Staff, Abandons Most Virus Work and Pivots to Cancer in Sanofi Deal
As part of a major reorganization, Vir Biotechnology has discontinued the bulk of its virology work and pivoted to cancer in an exclusive licensing deal with Sanofi.
August 2, 2024
·
2 min read
·
Tristan Manalac
Legal
Sanofi Sues Sarepta Over Elevidys DMD Gene Therapy, Alleges Patent Infringement
Sarepta has been hit with another patent infringement lawsuit, this time from Sanofi and its subsidiary Genzyme alleging that the biotech used protected technology related to AAV vectors.
August 1, 2024
·
2 min read
·
Tristan Manalac
Deals
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi announced the completion of its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, underscoring the company’s commitment to pursuing differentiated and potential best-in-class medicines that build upon our existing strengths and capabilities..
May 30, 2024
·
5 min read
Business
Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee
Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President, has been named Executive Vice President, Global Head of Corporate Affairs.
June 21, 2024
·
3 min read
1 of 1,356
Next
